

# The Biotech Growth Trust PLC


## Information as at 31 July 2025

### Investment Objective and Benchmark Index

The Biotech Growth Trust PLC (the "Company") seeks capital appreciation through investment in the worldwide biotechnology industry. Performance is measured against its benchmark index, the NASDAQ Biotechnology Index (net, total return, sterling adjusted).

### Five Year Performance (%)

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed; an investor may receive back less than the original amount invested.



Source: Frostrow Capital LLP.

\* Index – With effect from 01.10.2024, the index changed to net total return, prior to this date it was capital return.

### Ten Largest Holdings as at 31 July 2025 (% of total investments)

Name	Total
Vertex Pharmaceuticals	5.3
Alnylam Pharmaceuticals	4.8
Avidity Biosciences	4.6
Argenx	4.2
Zai Lab	4.1
CG oncology	4.1
Axsome Therapeutics	3.3
Akeso	2.9
Dyne Therapeutics	2.9
Agios Pharmaceuticals	2.8
<b>Total</b>	<b>39.0</b>



**Portfolio Manager**  
Geoffrey Hsu

**Portfolio Manager**  
Josh Golomb

# orbimed

### Fast Facts

As at 31 July 2025

**Launch Date** June 1997

**AIC Sector** Biotechnology & Healthcare

Date of Appointment of OrbiMed  
19 May 2005

### Annual Management Fee (payable by the Company)

0.65% of net assets plus 0.30% per annum on the Company's market capitalisation up to £500m, 0.20% on market capitalisation above £500m and 0.10% on market capitalisation over £1bn

**Performance fee** See Annual Report for details

**Ongoing Charges Ratio (OCR) \*** 1.1%

**Continuation Vote** 2025 AGM and every 5th AGM thereafter

**Year / interim end** 31 March / 30 September

**Capital Structure** 24,811,969 Ordinary Shares of 25p

### Trust Characteristics

**Number of Holdings** 69

**Net Assets (£m)** £227.0m

**Market Capitalisation (£m)** £206.4m

**Dividend Policy** It is not anticipated that the Company will pay a dividend

**Gearing (AIC basis)** 8.6%

**Leverage\*\*** Gross 113.6%  
Commitment 112.3%

**Share Price (p)** 832.00

**NAV (p)** 915.02

**(Discount) / Premium** (9.1%)

**Portfolio Turnover p.a.** 163.7%

**Active Share\*\*\*** 70.6%

# The Biotech Growth Trust PLC

## Information as at 31 July 2025

### Geographical Breakdown as at 31 July 2025 (%)†

North America	63.0%
China	24.1%
Continental Europe	10.5%
Unquoted ‡	2.1%

**Total** **100.0%**

† Calculation based on economic exposure and expressed as a % of the total economic exposure. This includes all derivatives as an economically equivalent position in the underlying holding.

‡ No more than 10% of gross assets will be invested in unquoted investments at the time of acquisition. This limit includes any investment or commitment to invest in private equity funds managed by OrbiMed or an affiliate thereof. Investments or commitments to invest in such private equity funds will be limited to US\$15m, after the deduction of proceeds of disposal and other returns of capital. Of the 2.1% unquoted investments, 1.3% in US, 0.4% was in China, and 0.4% was in Asia.

Source: All portfolio information sourced from Frostrow Capital LLP

### Discrete Performance – Calendar Years (%)

Percentage Growth 12 Month Return	2020	2021	2022	2023	2024	YTD
NAV	52.4	-23.1	-13.6	-7.2	1.2	-4.6
Share Price	67.7	-24.6	-22.1	-3.5	-4.4	-2.7
Index	22.1	0.2	-0.3	-1.7	0.7	-1.7

### Standardised Discrete Performance (%)

Percentage Growth 12 Month Return	Jul 20-Jul 21	Jul 21-Jul 22	Jul 22-Jul 23	Jul 23-Jul 24	Jul 24-Jul 25
NAV	4.7	-26.9	-7.2	29.5	-17.9
Share Price	0.7	-30.7	-6.1	28.8	-19.1
Index	14.6	-13.2	0.1	17.5	-10.2

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed.

Source: Index & NAV (total return; fully diluted) & Share Price (total return) – Frostrow Capital LLP.

\*Calculated at the financial year end, includes management fees and all other operating expenses, excludes performance fees.


\*\*The Board has set the leverage limit for both the Gross and the Commitment basis at 130% of the Company's Net Asset Value.

\*\*\*Active Share is expressed as a percentage and shows the extent to which a fund's holdings and their weightings differ from those of the fund's benchmark index. A fund that closely tracks its index might have a low Active Share of less than 20% and be considered passive, while a fund with an Active Share of 60% or higher is generally considered to be actively managed.

### Investment Policy

In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. The Company will not invest more than 15% of the value of its gross assets in any one individual stock at the time of acquisition. No more than 10% of gross assets will be invested in unquoted investments at the time of acquisition. This limit includes any investment or commitment to invest in private equity funds managed by OrbiMed or an affiliate thereof. Investments or commitments to invest in such private equity funds will be limited to US\$15m, after the deduction of proceeds of disposal and other returns of capital. The Company's borrowing policy is that borrowings will not exceed 20% of value of the Company's net assets. The Company may be unable to invest directly or efficiently in certain countries or share classes. In these circumstances, the Company may gain exposure by investing indirectly through swaps or other derivative instruments. Exposure to these financial instruments will count towards and be subject to the following limits: Derivative transactions (excluding equity swaps) can be used to mitigate risk and/or enhance return and will be restricted to an aggregate net exposure of 5% of the value of the gross assets measured at the time of the relevant transaction; Equity swaps may be used for efficient portfolio management purposes and aggregate net counterparty exposure through a combination of derivatives and equity swap transactions is restricted to 12% of the value of the gross assets of the Company at the time of the transaction.

### Return vs Volatility (Annualised since Date of Appointment of OrbiMed) – Chart (%)



### Commentary

In July, the NAV per share was up 17.4%, the share price was up 16.2% and the benchmark NASDAQ Biotechnology Index (net, total return, sterling adjusted) was up 9.4%.

Biotech outperformed the general markets in July. In late July, the Trump administration agreed to a broad 15% tariff rate between the EU and U.S., which would likely apply to pharmaceutical products. While not ideal, this 15% rate is much better than the potential 200% tariffs on pharmaceuticals that Trump had initially suggested in early July. Additionally, on the last day of July, President Trump sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the U.S. to match the lowest price offered in other developed nations (known as the most-favored-nation, or MFN, price). The MFN concept had already been announced via the executive order that Trump signed in May. Although there are still many open questions as to how the policy could be implemented, we still view any potential impact as likely minimal, given the types of drugs being addressed and the policy's focus on the smaller Medicaid market.

There were a couple of notable mergers and acquisitions announced in July. Merck & Co. agreed to pay \$10 billion to buy Verona Pharma, gaining access to a potential multibillion-dollar new drug to treat chronic obstructive pulmonary disease. Sanofi announced it will pay \$1.15 billion upfront to buy privately-held Vicebio and gain access to non-mRNA vaccine candidates against respiratory syncytial virus, metapneumovirus, and parainfluenza. While neither target was held in the portfolio, we expect continued M&A activity for the balance of the year that should benefit the sector generally.

Akeso, Nanjing Leads Biolabs Co, and Argenx were the largest positive contributors to performance during the month. Akeso outperformed after widely reported rumors that its partner Summit Therapeutics was in advanced discussions with AstraZeneca to sign a \$15 billion commercialization deal for its experimental lung cancer drug ivonescimab. Akeso, the originator of ivonescimab, is eligible to receive significant milestones and royalties on any ex-China sales of the drug. A potential partnership with a global pharma leader like AstraZeneca would validate Akeso's innovation and increase the future economic potential of the drug to Akeso. Nanjing Leads Biolabs' stock price surged in late July 2025 after the company went public on the Hong Kong Stock Exchange. OrbiMed was able to secure a cornerstone allocation in the IPO in a well-subscribed offering. The company's lead candidate, LBL-024 (a potential best-in-class bispecific antibody), showed a high objective response rate for advanced neuroendocrine carcinoma in a recent Phase 1b/2 trial, with potential to expand to larger indications. This compound has been granted Breakthrough Therapy Designation in China and Orphan Drug Designation in the US. We continue to believe that innovation in China will become an increasingly important part of the global biotechnology landscape. OrbiMed is uniquely positioned to take advantage of those opportunities given our local presence in Shanghai and Hong Kong. Argenx outperformed in July after it reported global net sales of its drug Vyvgart for 2Q25 that far exceeded market expectations.

Natera, Forte Biosciences, and Structure Therapeutics were the largest negative contributors to performance during the month. Natera underperformed in July after a notable wave of insider stock sales during the month. Forte stock declined in July after completing a large equity capital raise. Structure Therapeutics' stock price declined on no fundamental news.

### Codes

<b>Sedol</b>	0038551
<b>ISIN</b>	GB0000385517
<b>Legal Entity Identifier (LEI)</b>	549300Z41EP32MI2DN29
<b>Global Intermediary Identification Number (GIIN)</b>	U1MQ70.99999.SL.826
<b>Bloomberg</b>	BIOG LN
<b>EPIC</b>	BIOG

### Discount / Premium Control Mechanism

The Directors have adopted an active discount management policy to establish and support an improved rating in the Company's shares through the use of share buybacks, with a view to limiting the discount to NAV per share at which the shares trade to no more than 6%. Shares bought back will be cancelled.

### How to Contact Us

**Frostrow Capital LLP**  
 25 Southampton Buildings  
 London, WC2A 1AL

Tel.: 0203 008 4910  
 Fax: 0203 043 8889

Website: [www.frostrow.com](http://www.frostrow.com)  
 Email: [info@frostrow.com](mailto:info@frostrow.com)

### Risk Warnings

This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Before investing in the Company, or any other investment product, you should satisfy yourself as to its suitability and the risks involved, and you may wish to consult a financial adviser.

Any return you receive depends on future market performance and is uncertain. The Company does not seek any protection from future market performance so you could lose some or all of your investment. Shares of the Company are bought and sold on the London Stock Exchange (LSE). The price you pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company. Usually, at any given time, the price you pay for a share will be higher than the price you could sell it. For further information on the principal risks the Company is exposed to please refer to the Company's Annual Report or Investor Disclosure Document available at [www.biotechgt.com](http://www.biotechgt.com). The Company can borrow to purchase investments, this could potentially magnify any losses or gains made by the Company.

### Target Market

The Company is suitable for investors seeking an investment that aims to deliver total returns over the longer term (at least five years), is compatible with the needs for retail clients, professional clients and eligible counterparties, and is eligible for all distribution channels.

The Company may not be suitable for investors who are concerned about short-term volatility and performance, have low or no risk tolerance or are looking for capital protection, who are seeking a guaranteed or regular income, or a predictable return profile. The Company does not offer capital protection.

### Value Assessment

Frostrow Capital LLP has conducted an annual Value Assessment on the Company in line with Financial Conduct Authority ("FCA") rules set out in the Consumer Duty regulation. The Assessment focuses on the nature of the product, including benefits received and its quality, limitations that are part of the product, expected total costs to clients and target market considerations.

Within this, the assessment considers quality of services, performance of the Company (against both benchmark and peers), total fees (including management fees and entry and exit fees as applicable to the Company), and also considers whether vulnerable consumers are able to receive fair value from the product.

Frostrow Capital LLP concluded that the Company is providing value based on the above assessment.

### Important Information

The Biotech Growth Trust PLC is a public limited company whose shares are listed on the LSE and is registered with HMRC as an investment trust. The Company has an indeterminate life, although shareholders consider and vote on the continuation of the Company every five years (the next such vote will be held in 2025).

This financial promotion is issued by Frostrow Capital LLP which is authorised and regulated by the FCA.

---